Executive Summary
CHAPTER1．Alectinib Hydrochloride
CHAPTER2．Apatinib Mesylate
CHAPTER3．Apremilast
CHAPTER4.Asunaprevir
CHAPTER5．Ataluren
CHAPTER6．Belinostat
CHAPTER7．Ceritinib
CHAPTER8．Chidamide
CHAPTER9．Daclatasvir Dihydrochloride
CHAPTER10．Delamanid
CHAPTER11．EliglustatTartrate
CHAPTER12．Empagliflozin
CHAPTER13．Finafloxacin
CHAPTER14．Idelalisib
CHAPTER15．IpragliflozinL．Proline
CHAPTER16．Luseogliflozin Hydrate
CHAPTER17．Naloxegol Oxalate
CHAPTER18．Nintedanib Esylate
CHAPTER19．Olaparib
CHAPTER20．Oritavancin Diphosphate
CHAPTER21．Phenothrin
CHAPTER22．Ripasudil Hydrochloride Hyrdrate
CHAPTER23．Suvorexant
CHAPTER24．Tasimelteon
CHAPTER25．Tavaborole
CHAPTER26．Tedizolid Phosphate
CHAPTER27．Tofogliflozin Hydrate
CHAPTER28．Umeclidinium Bromide
CHAPTER29．Vaniprevir
CHAPTER30．VonoprazanFumarate
CHAPTER31．VorapaxarSulfate
Appendix.Abbreviation
AppendixII.SalesWorldwider2014—2015)
AppendixIII.WorldwideApproved NCEs(2001—2015)
Append&IV.WorldwideApproved NCEs(SortedbyIndication2001—2015)

《The Pharmaceutical Index》将是第一本最新追踪全球每年上市新药，真正为药物研发相关人员提供核心数据的参考书籍。全球每年上市约20-50个新药，《The Pharmaceutical Index》将每个药物的专利、化学、药学、药理学、药代动力学、毒理学、临床研究等数万页文献资料浓缩、